Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

GENERAL COUNSEL

Chief Executive Officer

COO AND CDO

Chief Operating Officer

CHIEF SCIENTIFIC OFFICER

General Counsel

CFO AND CHIEF BUSINESS OFFICER

Chief Medical Officer

Chief Scientific Officer

See Below

Chief Financial Officer

Executive VP, Research

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is ATH-1017 Fosgonimeton, a small molecule designed to enhance the activity of hepatocyte growth factor (HGF) and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an orally available, brain-penetrant small molecule positive modulator of HGF/MET which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-01-05	Premium	sold	Premium	Premium	Premium	GENERAL COUNSEL
2024-01-05	Premium	sold	Premium	Premium	Premium	Chief Executive Officer
2024-01-05	Premium	sold	Premium	Premium	Premium	COO AND CDO
2024-01-05	Premium	sold	Premium	Premium	Premium	CEO
2024-01-05	Premium	sold	Premium	Premium	Premium	Chief Operating Officer
2024-01-05	Premium	sold	Premium	Premium	Premium	CHIEF SCIENTIFIC OFFICER
2024-01-05	Premium	sold	Premium	Premium	Premium	General Counsel
2024-01-05	Premium	sold	Premium	Premium	Premium	CFO AND CHIEF BUSINESS OFFICER
2024-01-04	Premium	acquired	Premium	Premium	Premium	COO AND CDO
2024-01-04	Premium	acquired	Premium	Premium	Premium	General Counsel
2024-01-04	Premium	acquired	Premium	Premium	Premium	Chief Operating Officer
2024-01-04	Premium	acquired	Premium	Premium	Premium	GENERAL COUNSEL
2024-01-04	Premium	acquired	Premium	Premium	Premium	CHIEF SCIENTIFIC OFFICER
2024-01-04	Premium	acquired	Premium	Premium	Premium	Chief Medical Officer
2024-01-04	Premium	acquired	Premium	Premium	Premium	Chief Executive Officer
2024-01-04	Premium	acquired	Premium	Premium	Premium	CEO
2024-01-04	Premium	acquired	Premium	Premium	Premium	CFO AND CHIEF BUSINESS OFFICER
2023-12-29	Premium	bought	Premium	Premium	Premium	-
2023-12-28	Premium	bought	Premium	Premium	Premium	-
2023-12-27	Premium	bought	Premium	Premium	Premium	-
2023-11-20	Premium	acquired	Premium	Premium	Premium	Chief Scientific Officer
2023-11-20	Premium	acquired	Premium	Premium	Premium	CHIEF SCIENTIFIC OFFICER
2023-06-07	Premium	bought	Premium	Premium	Premium	See Below
2023-06-05	Premium	bought	Premium	Premium	Premium	See Below
2023-06-02	Premium	bought	Premium	Premium	Premium	See Below

ATHA - Athira Pharma Inc Stock Price, Fair Value and News

Latest Insider Trading transactions for ATHA